stockrowArcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
Follow ARQT
Alert me
Arcutis Biotherapeutics, Inc. (ARQT) EBITDA
Arcutis Biotherapeutics, Inc.'s EBITDA for fiscal 2025 was −$9.7M, compared with −$133.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was $36.9M. Over the past ten years it has ranged from −$302.9M (fiscal 2022) to −$4.1M (fiscal 2017); the current reading is higher than 89% of that period. EBITDA has risen for 3 consecutive fiscal years. Arcutis Biotherapeutics, Inc. ranks 38th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$9.7M | — |
| FY2024 | −$133.3M | — |
| FY2023 | −$247.3M | — |
| FY2022 | −$302.9M | — |
| FY2021 | −$202.6M | — |
| FY2020 | −$136.5M | — |
| FY2019 | −$43.4M | — |
| FY2018 | −$19.7M | — |
| FY2017 | −$4.1M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $9.8M | (41.37%) |
| Jun 2026 | $16.8M | — |
| Mar 2026 | −$8.7M | — |
| Dec 2025 | $19.0M | 122.10% |
| 27 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. | $36.9M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$19.0M |
| TNGX Tango Therapeutics, Inc. compare | −$137.8M |
| ABCL AbCellera Biologics Inc. compare | −$192.6M |
| EWTX Edgewise Therapeutics, Inc. compare | −$221.9M |
| DNTH Dianthus Therapeutics, Inc. compare | −$227.5M |
| DFTX Definium Therapeutics, Inc. compare | −$227.7M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$261.9M |
| RLAY Relay Therapeutics, Inc. compare | −$311.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ARQT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement